Vaccination of high risk breast cancer patients with heptavalent antigen - keyhole limpet hemocyanin conjugate [OPT 22] plus the immunological adjuvant QS21

Trial Profile

Vaccination of high risk breast cancer patients with heptavalent antigen - keyhole limpet hemocyanin conjugate [OPT 22] plus the immunological adjuvant QS21

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs Adagloxad simolenin (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Dec 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Aug 2007 Status change from suspended to in progress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top